Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06244771 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Frontier Medicines Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 403
- Enrollment target
- 20
- Study locations
NCT06244771: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Frontier Medicines Corporation.
NCT06244771 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Frontier Medicines Corporation. The registered enrollment target is 403 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06244771, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Frontier Medicines Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 403 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
Primary Outcome
Number of participants with Dose Limiting Toxicities (DLTs)
Conditions Studied
Interventions
- DRUG FMC-376
Study Locations (20)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- Community Clinical Trials - Kingwood
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
- UT Health San Antonio - San Antonio
California
- University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center - La Jolla
- University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center - Orange
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center - San Francisco
South Australia
- Icon Cancer Centre Kurralta Park - Kurralta Park
- GenesisCare North Adelaide - North Adelaide
Florida
- Florida Cancer Specialists and Research Institute - Lake Mary
Indiana
- Northwest Cancer Centers - Dyer
Kansas
- The University of Kansas Cancer Center - Fairway
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
What NCT06244771 shows while recruiting
NCT06244771 is an interventional study that assigns participants to a tested intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (38% lower).
The record links to 8 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which FMC-376 is the first listed.
NCT06244771 names 20 study sites across 14 states, led by Texas, California, South Australia.
Frequently Asked Questions
What is clinical trial NCT06244771 about?
NCT06244771 is a clinical study titled "A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors". The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants wi...
What is the current status of trial NCT06244771?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 403 participants. The study started on 2024-02-12. Estimated completion is 2028-04.
What conditions does trial NCT06244771 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Adult, Metastatic Solid Tumor.
What interventions are being tested in trial NCT06244771?
The interventions under investigation include: FMC-376 (DRUG).
Who is sponsoring clinical trial NCT06244771?
This trial is sponsored by Frontier Medicines Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06244771 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06244771's enrollment target sits among peer trials
403 97th of 454 higher than 358 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05647122 · 403 participants · Phase 1
First in Human Study of AZD9592 in Solid Tumors
- NCT05674799 · 403 participants · NA
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
- NCT05611242 · 404 participants · Phase 3
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI